DE69124387T2 - Rahmenbau-mutierte antikörper und ihre herstellung - Google Patents

Rahmenbau-mutierte antikörper und ihre herstellung

Info

Publication number
DE69124387T2
DE69124387T2 DE69124387T DE69124387T DE69124387T2 DE 69124387 T2 DE69124387 T2 DE 69124387T2 DE 69124387 T DE69124387 T DE 69124387T DE 69124387 T DE69124387 T DE 69124387T DE 69124387 T2 DE69124387 T2 DE 69124387T2
Authority
DE
Germany
Prior art keywords
muted
antibodies
production
frame
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69124387T
Other languages
English (en)
Other versions
DE69124387D1 (de
DE69124387T3 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Technology Group Inter Corporate Licensing Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10682322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69124387(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of DE69124387D1 publication Critical patent/DE69124387D1/de
Application granted granted Critical
Publication of DE69124387T2 publication Critical patent/DE69124387T2/de
Publication of DE69124387T3 publication Critical patent/DE69124387T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69124387T 1990-09-17 1991-09-16 Rahmenbau-mutierte antikörper und ihre herstellung Expired - Lifetime DE69124387T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9020282 1990-09-17
GB909020282A GB9020282D0 (en) 1990-09-17 1990-09-17 Altered antibodies and their preparation
PCT/GB1991/001578 WO1992005274A1 (en) 1990-09-17 1991-09-16 Framework mutated antibodies and their preparation

Publications (3)

Publication Number Publication Date
DE69124387D1 DE69124387D1 (de) 1997-03-06
DE69124387T2 true DE69124387T2 (de) 1997-05-15
DE69124387T3 DE69124387T3 (de) 2011-02-17

Family

ID=10682322

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69124387T Expired - Lifetime DE69124387T3 (de) 1990-09-17 1991-09-16 Rahmenbau-mutierte antikörper und ihre herstellung

Country Status (20)

Country Link
US (5) USRE46877E1 (de)
EP (1) EP0549581B2 (de)
JP (1) JPH06502762A (de)
KR (1) KR100217212B1 (de)
AT (1) ATE148172T1 (de)
AU (1) AU660151B2 (de)
CA (1) CA2091769C (de)
DE (1) DE69124387T3 (de)
DK (1) DK0549581T3 (de)
ES (1) ES2097808T3 (de)
GB (1) GB9020282D0 (de)
GR (1) GR3023252T3 (de)
ID (1) ID1044B (de)
IE (1) IE913257A1 (de)
IL (1) IL99499A (de)
MX (1) MX9101117A (de)
MY (1) MY111682A (de)
NZ (1) NZ239826A (de)
WO (1) WO1992005274A1 (de)
ZA (1) ZA917407B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
WO1996036359A1 (en) * 1995-05-18 1996-11-21 Ortho Pharmaceutical Corporation Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
CN1541226A (zh) * 2001-05-18 2004-10-27 ���ָ��Ӣ��ķ�������Ϲ�˾ CD44v6特异性的抗体
GB2376466A (en) * 2001-06-14 2002-12-18 Mark Frewin TRX1 antibody
US8165535B2 (en) * 2006-06-04 2012-04-24 Samsung Electro-Mechanics Systems, methods and apparatuses for complementary metal oxide semiconductor (CMOS) antenna switches using switched resonators
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
JP4898452B2 (ja) 2003-12-05 2012-03-14 マルチミューン ジーエムビーエイチ 治療および診断用抗Ｈｓｐ７０抗体
EP2336177A1 (de) * 2004-08-04 2011-06-22 Amgen, Inc DKK-1 Antikörper
AP2007004250A0 (en) * 2005-05-24 2007-12-31 Avestha Gengraine Tech Pvt Ltd Recombinant method for the production of a monoclonal antibody to cd52 for the treatment of chronic lymphocytic leukemia
EA029481B1 (ru) 2007-01-05 2018-04-30 Юнивэсэти Оф Цюрих Способ получения человеческого рекомбинантного антитела, специфично связывающего вариант эндогенного белка, формирующий аномальные патологические белковые структуры путем агрегации, олигомеризации или образования фибрилл
WO2008110372A1 (en) 2007-03-13 2008-09-18 University Of Zurich Monoclonal human tumor-specific antibody
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
EP2185592B1 (de) 2007-09-13 2013-01-23 University Of Zurich Prorektorat Forschung Monoklonaler amyloid-beta (abeta)-spezifischer antikörper und seine verwendung
EP2352764B1 (de) 2008-10-14 2018-03-28 Ablynx N.V. Aminosäuresequencen die an humanes cd4 und cxcr4, ccr5, tlr4, alphav integrin, beta3-integrin,beta1-integrin, humanes alpha2-integrin, cd81, sr-bi, claudin-1, claudin-6 bzw. claudin-9 binden und den viruseintritt neutralisieren.
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
SI2509409T1 (sl) 2009-12-10 2016-12-30 Regeneron Pharmaceuticals, Inc. Miši, ki tvorijo protitelesa težke verige
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
UA115657C2 (uk) 2011-09-19 2017-12-11 Аксон Ньюросайєнс Сє Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
WO2013063186A2 (en) 2011-10-26 2013-05-02 Novartis Animal Health Us, Inc. Monoclonal antibodies and methods of use
WO2013093122A2 (en) 2011-12-23 2013-06-27 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
CA2861793C (en) 2011-12-28 2023-08-01 Immunoqure Ag Method of providing monoclonal auto-antibodies with desired specificity
ES2911663T3 (es) 2013-07-03 2022-05-20 Immunoqure Ag Anticuerpos humanos anti-IFN-alfa
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652447A (en) 1979-04-26 1987-03-24 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human helper T cells
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4695459A (en) 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US4681760A (en) 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
AU625613B2 (en) 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
JP2646007B2 (ja) 1988-01-30 1997-08-25 財団法人 化学及血清療法研究所 抗ｈｉｖ抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗ｈｉｖキメラ抗体ならびにその製法
ATE95068T1 (de) 1988-02-12 1993-10-15 British Tech Group Modifizierte antikoerper.
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
EP0365209A3 (de) 1988-10-17 1990-07-25 Becton, Dickinson and Company Aminosäuresequenz des Anti-leu 3a
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69020914T2 (de) 1989-01-23 1996-03-07 Abbott Lab Monoklonale Antikörper von Ratten gegen menschliche Antigene und Verfahren zu deren Herstellung.
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
JPH0353894A (ja) 1989-07-21 1991-03-07 Calpis Food Ind Co Ltd:The 抗ヒトｃｄ４ペプチドに対するモノクローナル抗体
GB8925590D0 (en) 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US6407213B1 (en) * 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody

Also Published As

Publication number Publication date
GR3023252T3 (en) 1997-07-30
JPH06502762A (ja) 1994-03-31
GB9020282D0 (en) 1990-10-31
KR930702535A (ko) 1993-09-09
KR100217212B1 (ko) 1999-10-01
AU660151B2 (en) 1995-06-15
ES2097808T3 (es) 1997-04-16
DE69124387D1 (de) 1997-03-06
US20070212753A1 (en) 2007-09-13
US7098006B1 (en) 2006-08-29
AU8508891A (en) 1992-04-15
CA2091769A1 (en) 1992-03-18
US6767996B1 (en) 2004-07-27
NZ239826A (en) 1992-12-23
EP0549581A1 (de) 1993-07-07
DK0549581T3 (da) 1997-05-26
EP0549581B1 (de) 1997-01-22
EP0549581B2 (de) 2010-04-28
MX9101117A (es) 1992-05-04
IL99499A0 (en) 1992-08-18
DE69124387T3 (de) 2011-02-17
USRE46877E1 (en) 2018-05-29
ZA917407B (en) 1992-06-24
MY111682A (en) 2000-11-30
WO1992005274A1 (en) 1992-04-02
ATE148172T1 (de) 1997-02-15
USRE43898E1 (en) 2013-01-01
IE913257A1 (en) 1992-02-25
IL99499A (en) 2006-08-20
ID1044B (id) 1996-10-28
CA2091769C (en) 2002-07-23

Similar Documents

Publication Publication Date Title
ATE148172T1 (de) Rahmenbau-mutierte antikörper und ihre herstellung
ATE157990T1 (de) Monoklonale antikörper gegen den humanen alpha/beta-t-zellenrezeptor, ihre herstellung und verwendung
ES2146627T3 (es) Metalocenos de bis-fluorenilo y su uso.
DE3581578D1 (de) Antikoerper, herstellung und verwendung.
DE69001275D1 (de) Satz zur herstellung und abscheidung von endothelzellen.
ATE166882T1 (de) Monoklonale antikörper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
DE3785967T2 (de) Monoklonale Antikörper gegen C5A und DES-ARG74-C5A, ihre Herstellung und ihre Verwendung.
DE3788148D1 (de) Monoklonale Antikörper und deren Verwendung.
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
ATE114713T1 (de) Biomasse zur produktion von virus/virusantigen.
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DE68907735T2 (de) Genfragmente, die die variable Region eines Anti-HIV-Antikörpers codieren, von diesen exprimierte chimäre Anti-HIV-Antikörper und Verfahren zu deren Herstellung.
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
FI861692A (fi) En ny tumoerassocierad antigen.
DE3583296D1 (de) Oncofetal spezifische monoklonale antikoerper, deren herstellung und verwendung.
EP0299354A3 (en) Monoclonal antibodies against protein e7 of the human papilloma virus type 16, their production process and their use
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
DE3885975D1 (de) Monoklonale Antikörper gegen menschliche alpha-Atrialnatriüretic-Polypeptide und entsprechende Hybridome, deren Herstellung und Verwendung.
NO893818L (no) Produksjon og anvendelse av hybride, monoklonale antistoffer.
ATE56617T1 (de) Anti-urokinase monoklonaler antikoerper, seine herstellung und verwendung.
DE69124317T2 (de) Monoklonale Antikörper gegen Leptosphaeria
ATE89861T1 (de) Monoklonale antikoerper gegen c5a und des-arg74c5a, ihre herstellung und ihre verwendung.
ATE92102T1 (de) Genfragmente, die die variable region eines anti- hiv-antikoerpers codieren, von diesen exprimierte chimaere anti-hiv-antikoerper und verfahren zu deren herstellung.
DE69124294D1 (de) Monoklonale Antikörper gegen Mycosphaerella-Arten
ATE64616T1 (de) Oncofetal spezifische monoklonale antikoerper, deren herstellung und verwendung.

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Free format text: ERFINDER WIRD SPAETER GENANNT WERDEN

8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: BRITISH TECHNOLOGY GROUP INTER-CORPORATE LICEN, GB

8366 Restricted maintained after opposition proceedings